Pelthos Therapeutics
Durham, North Carolina, United States · Biotechnology, Healthcare, Health Care
Pelthos Therapeutics Inc. was formerly known as Chromocell Therapeutics Corp. Pelthos Therapeutics specializes in developing treatments for molluscum contagiosum infections. The company is known for its FDA-approved drug ZELSUVMI, which is the first prescription treatment for home use. Pelthos is committed to advancing patient care through innovative therapeutic solutions. It operates as a subsidi
Key facts
- Headquarters
- Durham, North Carolina, United States
- Employees
- 83
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (PTHS)
- Website
- pelthos.com
- Company page
Recent activity at Pelthos Therapeutics
- : Chromocell Therapeutics (date of first sale on the SEC Form D)
- : Pelthos to merge with Castle Creek Biosciences
- : Pelthos Therapeutics Appoints John M. Gay as Chief Financial Officer
- : Chromocell Therapeutics
- : Chromocell Therapeutics
- : Chromocell Therapeutics
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Pelthos Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2026 | Venture | $57.5M |
| Nov 2025 | Venture | $18.0M |
| Jul 2025 | Venture | $50.1M |
| Jul 2024 | Venture | $750K |
Leadership
- Melvin Whitehead, Senior Vice President, Operations
- Sai Rangarao, Chief Commercial Officer (CCO)
- John M. Gay, Chief Financial Officer
- Richard Malamut, Director
- Ezra Friedberg, Director
- Todd Davis, Director
- Eric Lang, Executive Officer
- Francis Knuettel, Executive Officer
- Carri Geer, Chief Technology Officer
- Suzie Paulson, Vice President of Human Resources
- Scott Plesha, Chief Executive Officer
Verified email and direct lines for Pelthos Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Companies similar to Pelthos Therapeutics
- Biofrontera · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- AIM ImmunoTech · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Aquestive Therapeutics, Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Retension Pharmaceuticals · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Os Therapies · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About Pelthos Therapeutics: questions and answers
What does Pelthos Therapeutics do?
Pelthos Therapeutics Inc. was formerly known as Chromocell Therapeutics Corp. Pelthos Therapeutics specializes in developing treatments for molluscum contagiosum infections. The company is known for its FDA-approved drug ZELSUVMI, which is the first prescription treatment for home use. Pelthos is committed to advancing patient care through innovative therapeutic solutions. It operates as a subsidi
Where is Pelthos Therapeutics headquartered?
Pelthos Therapeutics is headquartered in Durham, North Carolina, United States.
How many employees does Pelthos Therapeutics have?
Pelthos Therapeutics has about 83 employees.
Has Pelthos Therapeutics raised funding?
Yes. Fundz has recorded 4 funding events for Pelthos Therapeutics. The most recent, $57.5M, was in Oct 2026.
Who leads Pelthos Therapeutics?
Melvin Whitehead is a Senior Vice President, Operations at Pelthos Therapeutics.
What is the latest news on Pelthos Therapeutics?
On Oct 30, 2026, Chromocell Therapeutics
Is Pelthos Therapeutics a public company?
Yes. Pelthos Therapeutics is publicly traded under the ticker PTHS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy